Saturday 17 October 2026 Export TXMD’s income statement to Excel — free account

TherapeuticsMD, Inc.

TXMD Healthcare Drug Manufacturers Specialty & Generic

TherapeuticsMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 71.6% from fiscal 2024. In the quarter to June 2026, revenue fell 8.72%, EPS fell 80.0% and free cash flow grew 104.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.90 0.03 −1.55%

Follow TXMD

Alert me

Market cap: $22.3M
P/E: 0.0×
Fwd P/E: 18.9×
Dividend yield: —
F-score: 6/9
Altman Z: −34.36
Beneish M: −2.54
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	1	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 8.42%

Capital & Financial Ratios $m

Market Cap 22.34

Revenue 3.27

Net Income (0.22)

Free Cash Flow 3.10

Net Debt (9.19)

Current Ratio 3.22

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 18.90

P/S ratio 6.73

P/B ratio 0.81

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth 422.43%

Next 5Y EPS Growth 17.60%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 31.03%

10-year low 10-year high

P/B against its own 10 years 22.57%

10-year low 10-year high

EV/Sales against its own 10 years 71.50%

10-year low 10-year high

EV/FCF against its own 10 years 41.23%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	5	7	9
Receivables	3	4	4	3
Inventory	—	—	—	—
Other	4	4	3	4
	12	12	14	16

	2023	2024	2025	Q'26
Payables	0	0	0	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	7	5	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	(17.28%)	(45.84%)	(64.91%)
Cash Flow	0.00%	0.00%	(35.99%)
Earnings	0.00%	0.00%	0.00%
Book Value	(8.18%)	0.00%	(8.55%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	0	1	1	1	3
’24	0	0	1	1	2
’23	0	0	0	1	1
’22	1	0	0	69	70
’21	20	23	25	(66)	3
’20	12	11	19	23	65

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	0	1	0	2
’24	0	1	0	0	1
’23	(9)	(3)	(6)	(5)	(23)
’22	(18)	(21)	18	30	9
’21	(38)	(27)	(38)	48	(55)
’20	(39)	(56)	(34)	(30)	(159)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	0	1	0	2
’24	0	1	0	0	1
’23	(9)	(3)	(6)	(5)	(23)
’22	(18)	(21)	18	30	9
’21	(39)	(27)	(38)	46	(57)
’20	(40)	(56)	(34)	(31)	(161)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.01	0.01	—	—	—
’25	(0.06)	0.05	0.01	(0.05)	(0.05)
’24	(0.06)	(0.09)	(0.05)	0.02	(0.19)
’23	(0.37)	(0.24)	(0.32)	(0.06)	(0.98)
’22	(5.69)	12.39	(3.13)	7.94	11.96
’21	(5.50)	(5.50)	(5.50)	(5.00)	(21.50)
’20	(10.50)	(9.50)	(6.00)	(7.50)	(36.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	219.50	175.00	175.50	91.00	42.50	17.50	1.99	1.95	0.70	0.72	Analyst estimates 2026–2028 Powerpack
	High	508.50	415.00	383.00	304.50	146.50	137.50	30.50	6.49	2.75	2.44
People
People	Employees	159	173	241	348	400	416	1	1	1	1
	Revenue/emp, $m	0.12	0.10	0.07	0.14	0.16	0.01	69.96	1.30	1.76	3.02
Income, $m
Income, $m	Revenue	19	17	16	50	65	3	70	1	2	3
	Gross margin, %	78.38	84.28	83.00	87.24	75.37	45.51	98.00	100.00	100.00	100.00
	EBT	(90)	(77)	(133)	(176)	(184)	(79)	1	(8)	(2)	(1)
	EBT margin, %	(464.32)	(458.50)	(823.73)	(354.79)	(282.90)	(3,082.20)	1.54	(594.62)	(133.05)	(21.61)
	Net income	(90)	(77)	(133)	(176)	(184)	(172)	112	(10)	(2)	(1)
	Depreciation	0	0	1	1	4	1	1	1	1	1
Per share, $
Per share, $	Revenue	4.94	4.08	3.58	10.08	11.77	0.32	7.75	0.12	0.15	0.26
	Earnings	(23.00)	(18.50)	(29.50)	(36.00)	(36.00)	(21.50)	12.41	(0.98)	(0.19)	(0.05)
	Cash flow	(17.63)	(18.53)	(23.73)	(33.63)	(28.93)	(6.93)	1.04	(2.21)	0.10	0.21
	Capex	(0.32)	(0.20)	(4.74)	(4.85)	(0.29)	(0.28)	(0.04)	0.00	0.00	0.00
	Free cash flow	(17.95)	(18.73)	(28.47)	(38.48)	(29.22)	(7.21)	1.00	(2.21)	0.10	0.21
	Book value	32.51	31.60	21.67	1.87	(22.49)	(11.76)	3.89	2.81	2.37	2.32
	Shares, m	4	4	5	5	6	8	9	10	12	12
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.00	0.00	0.00
	P/S	60.48	76.81	53.25	12.01	5.14	55.69	0.81	18.68	5.63	6.24
	P/B	9.18	9.92	8.79	64.79	0.00	0.00	1.61	0.83	0.36	0.70
	EV/Sales	53.68	69.23	47.77	12.72	7.60	170.38	3.89	219.16	153.43	91.57
	EV/FCF	(14.76)	(15.09)	(6.00)	(3.33)	(3.06)	(7.64)	30.33	(12.16)	340.30	133.16
Cash, $m
Cash, $m	Operating cash flow	(69)	(76)	(107)	(166)	(159)	(55)	9	(23)	1	2
	Capex	(1)	(1)	(21)	(24)	(2)	(2)	0	—	—	—
	Free cash flow	(70)	(77)	(128)	(190)	(161)	(57)	9	(23)	1	2
Balance, $m
Balance, $m	Working capital	124	126	146	155	69	(133)	9	5	7	10
	Total debt	—	—	73	196	240	188	9	—	—	—
	Net debt	(132)	(127)	(88)	35	159	123	(49)	(4)	(5)	(7)
	Shareholders’ equity	127	130	98	9	(124)	(94)	35	29	27	27
Returns, %
Returns, %	ROA	(83.14)	(53.85)	(74.67)	(73.71)	(82.00)	(98.22)	86.17	(15.37)	(5.31)	(1.49)
	ROIC	0.00	(1,749.59)	(875.89)	(212.33)	(274.11)	(167.23)	0.00	(21.34)	(17.12)	(14.15)
	ROE	(94.33)	(59.77)	(116.62)	(330.09)	319.73	158.45	(383.04)	(31.90)	(7.70)	(2.10)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SCYX SCYNEXIS, Inc.	$38.9M	— (loss-making)	— (loss-making)	−8.56% (below 0%: shrinking)	n/m	−98.60% (below 0%: shrinking)	100.00%	(3,308.51%)	Compare
IXHL Incannex Healthcare Inc.	$36.1M	— (loss-making)	— (loss-making)	−92.31% (below 0%: shrinking)	n/m	+327.73% (above 0%: growing)	100.00%	0.00%	Compare
RMTI Rockwell Medical, Inc.	$32.2M	— (loss-making)	— (loss-making)	+10.63% (above 0%: growing)	n/m	−12.92% (below 0%: shrinking)	18.24%	(5.97%)	Compare
CPHI China Pharma Holdings, Inc.	$31.3M	— (loss-making)	— (loss-making)	−7.56% (below 0%: shrinking)	n/m	−113.57% (below 0%: shrinking)	8.82%	(150.99%)	Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc.	$26.5M	0.2×	—	—	n/m	+82.01% (above 0%: growing)	0.00%	0.00%	Compare
TXMD TherapeuticsMD, Inc.	$22.3M	— (loss-making)	18.9×	−8.72% (below 0%: shrinking)	−80.00% (below 0%: shrinking)	+104.46% (above 0%: growing)	100.00%	(93.90%)
AYTU Aytu BioPharma, Inc.	$21.8M	— (loss-making)	— (loss-making)	+6.42% (above 0%: growing)	n/m	+57.72% (above 0%: growing)	64.63%	(4.82%)	Compare
UPC Universe Pharmaceuticals INC	$20.9M	— (loss-making)	4.1×	−23.98% (below 0%: shrinking)	−110.15% (below 0%: shrinking)	−84.99% (below 0%: shrinking)	32.57%	0.00%	Compare
BGXXQ Bright Green Corporation	$13.9M	— (loss-making)	—	—	n/m	−1.46% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$28.9M	—	—	−8.06%	—	−7.19%	25.41%	(2.41%)

All 86 Drug Manufacturers Specialty & Generic stocks →

TherapeuticsMD, Inc. (TXMD) key facts

Concern: TherapeuticsMD, Inc. reported a net loss of $569,000.00, or a loss of $0.05 per share, for fiscal 2025.
Strength: TherapeuticsMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 71.6% from fiscal 2024.
TherapeuticsMD, Inc. (TXMD) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TXMD traded at $1.90, a market capitalization of $22.3 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 6.7× sales.
Return on equity was −2.10% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −34.36 (distress zone) for fiscal 2025.